Evaluating clinical effectiveness of SARS-CoV-2 vaccine in solid organ transplant recipients: A propensity score matched analysis

Mollie Tucker1 | Marwan M. Azar1 | Elizabeth Cohen2 | Geliang Gan3 | Yanhong Deng3 | Carlo Foppiano Palacios1 | Maricar Malinis1

1Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA
2Department of Pharmacy, Yale New Haven Health, New Haven, Connecticut, USA
3Yale Center for Analytical Sciences, Yale School of Public Health, New Haven, Connecticut, USA

Correspondence
Maricar Malinis, Section of Infectious Disease, Department of Internal Medicine, Yale School of Medicine P.O. Box 208022, New Haven, CT 06520–8022, USA.
Email: maricar.malinis@yale.edu

Abstract

Background: Solid organ transplant recipients (SOTRs) are at disproportionate risk for severe Coronavirus Disease 2019 (COVID-19). Vaccination is a key preventative strategy but is associated with decreased humoral responses among SOTR. Whether dampened immune responses correlate with reduced clinical effectiveness is unclear. Our study was designed to evaluate the clinical effectiveness of SARS-CoV-2 vaccination in the early vaccine era.

Methods: We conducted a retrospective cohort study comparing SARS-CoV-2 infection rates between SOTRs who received two doses of mRNA or one dose of Ad26.Cov2.S vaccine and those not fully vaccinated (partially vaccinated and unvaccinated). To evaluate clinical effectiveness of vaccine, cause-specific Cox regression model and modified Poisson regression model were built using the propensity score-matched cohort. Additionally, the clinical outcomes of COVID-19 of fully vaccinated and not fully vaccinated SOTR were compared.

Results: Of 2705 SOTRs, 1668 were included in our final matched analysis, which showed a 73% reduction of SARS-CoV-2 infection and 76% reduction of all-cause-mortality among fully vaccinated patients. Thirty-nine SOTRs developed SARS-CoV-2 infection, including nine fully vaccinated and 30 not fully vaccinated. Among fully vaccinated patients, 22% had severe/critical COVID-19 and 0% mortality versus not fully vaccinated SOTRs, of whom 37% had severe/critical COVID-19 and 6.67% COVID-19-related mortality.

Conclusion: In SOTRs, completion of primary vaccine series in the early vaccine era was associated with a significant reduction of COVID-19 and was protective against severe/critical disease and death. Further studies are needed to evaluate the clinical effectiveness of SARS-CoV-2 vaccination in the long-term.
INTRODUCTION

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) disproportionately affects patients who are immunocompromised and leads to worse outcomes in solid organ transplant recipients (SOTRs) than the general population, as seen in several studies.\textsuperscript{1–4} Vaccination is a key strategy to prevent SARS-CoV-2 infection and progression to severe disease. Early vaccine trials have shown high efficacy against COVID-19 in the general population, reported as 95% for BNT162b2 and 94.1% for mRNA-1273; however, patients on immunosuppressive therapy were excluded from these studies.\textsuperscript{5,6} Meanwhile, the Ad26.COV2.S recombinant adenovirus vaccine had 66.1% efficacy in preventing moderate to severe–critical COVID-19 in the general population excluding those with immunosuppressing conditions.\textsuperscript{7}

Due to impaired immunity in SOTRs, there is reasonable concern that available SARS-CoV-2 vaccines are less effective in this population. Brosh-Nissimov et al. found that 40% of fully vaccinated patients in Israel with breakthrough infections requiring hospitalization were immunocompromised.\textsuperscript{8} In conjunction with decreased vaccine effectiveness, significantly reduced humoral immune response as evidenced by lower levels of anti-spike IgG antibodies has been documented in fully vaccinated liver, kidney, heart, and lung transplant recipients following mRNA vaccination compared to nonimmunocompromised vaccine recipients.\textsuperscript{9–12}

Due to concerns about suboptimal protection with a two-dose series, the impact of additional vaccine doses on humoral immunity has been evaluated and is shown to increase likelihood of antibody response for SOTRs.\textsuperscript{13,14} Based on these findings, the US Food and Drug Administration authorized a third primary vaccine dose 28 days after the second dose for immunocompromised patients on August 12, 2021, and the Centers for Disease Control and Prevention (CDC) subsequently updated their recommendations accordingly.\textsuperscript{15} Furthermore, the CDC recommended an additional booster dose (4th dose), now at 3 months following completion of the primary series, although little real-world data are available to support this practice. In parallel with mounting evidence of decreased humoral immune response to SARS-CoV-2 vaccination in SOTR, studies on clinical outcomes of vaccinated SOTRs, pertaining to prevention of infection, severe disease, and death, have been emerging. A multicenter study demonstrated increased risk of breakthrough infection in fully vaccinated SOTRs compared to the general population.\textsuperscript{16} Despite this, there were lower rates of symptomatic COVID-19 in fully vaccinated versus unvaccinated SOTRs at a time when recommendations for primary series included two mRNA vaccine doses.\textsuperscript{17}

To determine the clinical effectiveness of SARS-CoV-2 vaccine in our SOTR cohort, we performed a propensity score-matched analysis comparing fully vaccinated SOTRs to those who were either unvaccinated or partially vaccinated.

METHODOLOGY

2.1 Data collection

This was a retrospective cohort analysis of SOTR at any time posttransplant who received transplant care at Yale New Haven Hospital (New Haven, Connecticut) from January 1, 2021 to August 6, 2021, by means of electronic medical record (EMR) review. This study was approved by the Yale University Institutional Review Board (HIC # 2000027876).

We included SOTR age ≥18 years at the time of study period who had not had SARS-CoV-2 infection prior to January 1, 2021. Vaccination status as of August 6, 2021 was determined by the data communicated to EMR from the State of Connecticut, New York, and Rhode Island vaccine registries or from documentation of the provider. Patients with mixed vaccines, >2 mRNA vaccinations, or >1 Ad26.Cov2.S vaccination were excluded since these vaccination strategies were not in accordance with CDC guidelines at the time of the study. Since data were collected prior to the change in guidelines recommending an extra primary vaccine dose for immunosuppressed patients, fully vaccinated patients were defined as being ≥14 days from one dose of the Ad26.COV2.S vaccine or second dose of the mRNA-1273 or BNT162b2 vaccines as of August 6, 2021. Partially vaccinated patients were defined as either having received a single mRNA vaccine or ≤14 days from either two doses of an mRNA vaccine or one dose of the Ad26.Cov2.S vaccine. Unvaccinated patients were defined as those who did not receive any SARS-CoV-2 vaccine as of August 6, 2021.

Other clinical data collected were as follows: baseline demographics, comorbidities, type of organ transplantation, follow-up time from transplantation in years, maintenance immunosuppression regimen, and type of SARS-CoV-2 vaccination. We evaluated for SARS-CoV-2 infection in this cohort until August 6, 2021. SARS-CoV-2 infection was defined as the presence of a positive SARS-CoV-2 polymerase chain reaction test. If a patient was vaccinated, the timing of SARS-CoV-2 infection from vaccination (in days) was captured. For all patients who developed SARS-CoV2 infection, regardless of vaccination status, data pertaining to COVID-19-related treatment received, hospitalization, and clinical course were collected within 30 days of
infection diagnosis. For example, SOTRs who developed infection on August 6, 2021 were evaluated until September 5, 2021. The severity of COVID-19 was classified as per National Institute of Health definition.18

2.2 Statistical methods

Patients were classified as either fully vaccinated or not fully vaccinated. The latter group included unvaccinated or partially vaccinated SOTRs. Partially vaccinated and unvaccinated patients were grouped together for statistical analysis, since there were relatively fewer partially vaccinated patients, and these patients theoretically do not mount complete immunity.

Propensity scores were created using logistic regression model with vaccination status as outcome. Fully vaccinated patients were matched to not fully vaccinated patients 1:1 based on propensity score differences <1% to minimize confounders between these groups. A prior study has shown that SARS-CoV-2 vaccine acceptance correlated with age, sex, and race/ethnicity.19 Similarly, these factors are associated with severity of COVID-1920; hence, these were included as covariates. Comorbidities including obesity, diabetes, hypertension, stroke, chronic obstructive pulmonary disease (COPD), coronary artery disease, and congestive heart failure have also been shown to contribute to worse outcomes from COVID-19, so these were included as covariates.21 Mycophenolate was also selected as a covariate due to its association with severe COVID-19 outcome and with vaccine effectiveness.9–11,22 To further minimize transplant-related confounders, our covariates also included type of transplanted organ and years after transplant. Before and after propensity matching, differences between fully vaccinated and not fully vaccinated patients were evaluated using Student’s t-test for continuous variables and chi-square or Fisher’s Exact test for categorical variables.

Kaplan-Meier curves and log rank tests were used to assess probabilities of SARS-CoV-2 infection or all-cause mortality between fully vaccinated and not fully vaccinated patients. To evaluate the protective effect of vaccination, cause-specific Cox regression model and modified Poisson regression model were built using the propensity score-matched cohort.23,24 The follow-up time started from the index date, which was 14 days after receiving one dose of the Ad26.COV2.S vaccine or second dose of the mRNA-1273 or BNT162b2 for fully vaccinated patients (the same index date was used for not fully vaccinated patient in the matched pair), to the date of infection and censored at the last follow-up date or death. To further evaluate the protective effect of vaccination, all the above-mentioned analyses (propensity score matching, Cox regression, and Modified Poisson regression analyses) were also carried out among fully vaccinated and unvaccinated patients (excluding the partially vaccinated), as sensitivity analyses.

Descriptive statistics for patients who developed SARS-CoV-2 infection were also generated by vaccination status. A two-tailed p value <.05 was considered statistically significant. All analyses are conducted using SAS 9.4 (SAS institute, Cary, NC).

3 RESULTS

3.1 Prepropensity score matching

There were a total of 2705 SOTRs receiving care at our center during the study period. After excluding those with mixed vaccines, >2 mRNA vaccine doses, or >1 Ad26.COV2.S vaccine doses, and those with missing covariate information, there were 2361 patients (1427 fully vaccinated and 934 not fully vaccinated) considered for propensity matching (Figure S1). During the study period, the median time to first dose of vaccine among the 1511 vaccinated SOTRs prior to excluding those with missing covariate information was 92 days (interquartile range 70–113).

Prior to propensity matching, age, race, ethnicity, and percentage of patients with diabetes, hypertension, and COPD were significantly different between the fully vaccinated and not fully vaccinated (Table 1). The fully vaccinated group had an older mean age compared to not fully vaccinated group (58.52 vs. 53.70, p < .001). There was higher proportion of Black race and Latinx in the not fully vaccinated group (p < .05). There was higher proportion of Black race and Latinx in the not fully vaccinated group (p < .05). The cumulative number of vaccinated SOTRs and the number of infections per week of vaccinated and not fully vaccinated SOTR are illustrated in Figure 1.

3.2 Propensity score matching

After propensity matching, 1668 SOTRs were included (834 fully vaccinated and 834 not fully vaccinated). Clinical characteristics of SOTRs after propensity matching were balanced between groups and are described in Table 1. A total of 39 patients developed COVID-19
### TABLE 1  Baseline characteristics and outcomes before and after propensity score matching

|                      | Before propensity score match (N = 2631) | After propensity score match (N = 1668) |
|----------------------|-----------------------------------------|----------------------------------------|
|                      | Fully vaccinated (n = 1427) | Not fully vaccinated (n = 934) | p-Value | Fully vaccinated (n = 894) | Not fully vaccinated (n = 834) | p-Value |
| **Age – mean (SD)**  | 58.52 (13.64) | 53.70 (15.75) | <.001 | 55.19 (14.46) | 54.92 (15.22) | .71 |
| **Sex**              |                               |                                       |         |                               |                                       |         |
| Male                 | 866 (60.69%) | 593 (63.49%) | .17 | 521 (62.47%) | 518 (62.11%) | .88 |
| Female               | 561 (39.31%) | 341 (36.51%) | .31 | 313 (37.53%) | 316 (37.89%) | .88 |
| **Race**             |                               |                                       |         |                               |                                       |         |
| White                | 949 (66.50%) | 530 (56.75%) | <.001 | 491 (58.87%) | 501 (60.07%) | .95 |
| Black                | 281 (19.69%) | 260 (27.84%) | .21 | 214 (25.66%) | 211 (25.30%) | .87 |
| Asian                | 64 (4.48%) | 35 (3.75%) | .50 | 35 (4.20%) | 34 (4.08%) | .88 |
| Other                | 133 (9.32%) | 109 (11.67%) | .71 | 94 (11.27%) | 88 (10.55%) | .88 |
| **Ethnicity**        |                               |                                       |         |                               |                                       |         |
| Hispanic             | 168 (11.77%) | 151 (16.17%) | .002 | 127 (15.23%) | 119 (14.27%) | .58 |
| Non-Hispanic         | 1259 (88.23%) | 783 (83.83%) | .17 | 707 (84.77%) | 715 (85.73%) | .88 |
| **Comorbidity**      |                               |                                       |         |                               |                                       |         |
| Obesity              | 494 (34.62%) | 305 (32.66%) | .32 | 269 (32.25%) | 272 (32.61) | .88 |
| Diabetes             | 534 (37.42%) | 303 (32.44%) | .13 | 293 (35.13%) | 276 (33.09%) | .38 |
| Hypertension         | 1070 (74.98%) | 625 (66.92%) | <.001 | 576 (69.06%) | 579 (69.42%) | .87 |
| Stroke               | 68 (4.77%) | 42 (4.50%) | .76 | 44 (5.28%) | 34 (4.08%) | .25 |
| COPD                 | 36 (2.52%) | 8 (0.86%) | .003 | 4 (0.48%) | 6 (0.72%) | .53 |
| Coronary artery disease | 181 (12.68%) | 99 (10.60%) | .13 | 90 (10.79%) | 86 (10.31%) | .75 |
| Congestive heart failure | 166 (11.63%) | 120 (12.85%) | .38 | 96 (11.51%) | 100 (11.99%) | .76 |
| **Organ transplanted** |                         |                                       |         |                               |                                       |         |
| Heart                | 137 (9.60%) | 99 (10.60%) | .57 | 83 (9.95%) | 79 (9.47%) | .98 |
| Kidney               | 1006 (70.50%) | 665 (71.20%) | .57 | 595 (71.34%) | 602 (72.18%) | .98 |
| Liver                | 254 (17.80%) | 148 (15.85%) | .77 | 139 (16.67%) | 136 (16.31%) | .53 |
| Other                | 30 (2.10%) | 22 (2.36%) | .21 | 17 (2.04%) | 17 (2.04%) | .88 |
| **Years after transplant Mean (SD)** | 9.00 (7.89) | 9.09 (7.57) | .77 | 9.00 (8.00) | 9.23 (7.50) | .53 |
| **Immunosuppression** |                                         |                                       |         |                               |                                       |         |
| Mycophenolate        | 842 (59.00%) | 523 (56.00%) | .15 | 473 (56.71%) | 472 (56.39%) | .96 |
| Azathioprine         | 95 (6.66%) | 60 (6.42%) | .82 | 64 (7.67%) | 50 (6.00%) | .17 |
| Prednisone           | 875 (61.32%) | 566 (60.60%) | .73 | 525 (62.95%) | 505 (60.55%) | .31 |
| Tacrolimus           | 967 (67.76%) | 619 (66.27%) | .45 | 567 (67.99%) | 552 (66.19%) | .43 |
| Cyclosporine         | 110 (7.71%) | 56 (6.00%) | .11 | 50 (6.00%) | 54 (6.47%) | .69 |
| Belatacept           | 130 (9.11%) | 71 (7.60%) | .20 | 72 (8.63%) | 66 (7.91%) | .59 |
| Sirolimus            | 67 (4.70%) | 43 (4.60%) | .92 | 41 (4.92%) | 37 (4.44%) | .64 |
| Everolimus           | 16 (1.12%) | 8 (0.86%) | .53 | 8 (0.96%) | 7 (0.84%) | .80 |
| **Vaccine received** |                                         |                                       |         |                               |                                       |         |
| Ad26.COV2.S          | 64 (4.48%) | 4 (0.43%) | .15 | 45 (5.40%) | 4 (0.48%) | .17 |
| mRNA-1273            | 600 (42.05%) | 78 (8.35%) | .50 | 362 (43.41%) | 72 (8.63%) | .69 |
| BNT162b2             | 763 (53.47%) | 77 (8.24%) | .21 | 427 (51.20%) | 66 (7.91%) | .53 |
| None                 | 0 (0.00%) | 775 (82.98%) | .50 | 0 (0.00%) | 692 (82.97%) | .88 |

(Continues)
| Outcomes                             | Before propensity score match (N = 2631) | After propensity score match (N = 1668) |
|-------------------------------------|----------------------------------------|----------------------------------------|
|                                     | Fully vaccinated (n = 1427)            | Not fully vaccinated (n = 934)         | Fully vaccinated (n = 834) | Not fully vaccinated (n = 834) |
| SARS-CoV-2 infection                | 9 (0.63%)                              | 58 (6.21%)                             | 9 (1.08%)                 | 30 (3.60%)                  |
| Death from any cause                | 9 (0.63%)                              | 33 (3.53%)                             | 4 (0.48%)                 | 15 (1.80%)                 |
| Death due to COVID-19               | 0 (0%)                                 | 8 (0.86%)                              | 0 (0%)                    | 2 (0.24%)                  |

**p-Value**

Abbreviation: COPD, chronic obstructive pulmonary disease; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2.

**FIGURE 2** Kaplan-Meier curves of Covid infection or all-cause mortality among not fully vaccinated patients (red) compared to vaccinated patients (blue), with adjusted hazard ratios from Cox models.

3.3 Sensitivity analyses

To further evaluate the protective effect of vaccine, similar analyses were carried out using unvaccinated group as control. We found consistent findings with the prior analyses using the not fully vaccinated control. After propensity matching, 1658 SOTRs were included (829 fully vaccinated and 829 unvaccinated). Clinical characteristics of SOTRs after propensity matching were balanced between groups and are described in Table S1. Using a Cox regression model, the overall SARS-CoV-2 infection rate was found to be reduced by 62% (95% CI 18%–83%) in the fully vaccinated group compared to the unvaccinated patients. This was confirmed using a modified Poisson regression model that demonstrated a 60% decrease in the rate of infection among fully vaccinated SOTRs (95% CI 13%–82%). Additionally, the all-cause mortality rate was reduced by 79% (95% CI 16%–95%) among fully vaccinated SOTRs using the Cox regression model.
3.4 Characteristics of SOTR with SARS-CoV-2 infection

Clinical characteristics of the 39 patients with SARS-CoV-2 infection included in the propensity score matching are shown in Table 2.

All nine of the fully vaccinated SOTRs with breakthrough infections had received two doses of an mRNA vaccine (seven received BNT162b2, two received mRNA-1273). The mean time from second vaccination to SARS-CoV-2 infection in this group was 92 days (range 28–180). Of these nine patients, seven (78%) had asymptomatic or mild disease, and two patients had severe disease (requiring up to 5 liters/minute oxygen via nasal cannula). Six patients were not hospitalized, and half of these received monoclonal antibody (MAb) in the outpatient setting. The remaining three patients were hospitalized. One patient with mild disease was hospitalized due to symptoms of COVID-19 with associated delirium and received MAb without progression to severe disease. A second patient who presented with mild COVID-19 was hospitalized and received MAb while inpatient; however, this patient progressed to severe COVID-19 requiring remdesivir, dexamethasone, and tocilizumab and supplemental oxygen via nasal cannula up to 5 liters/minute. The third hospitalized patient who presented with severe disease required supplemental oxygen via nasal cannula up to 5 liters/minute, dexamethasone and remdesivir. None of the fully vaccinated SOTRs with breakthrough infection developed critical disease or died.

In the not fully vaccinated group, 18 (60%) had asymptomatic/mild disease, one patient (3%) had moderate disease, six had severe disease (requiring oxygen via nasal cannula requiring 1 liter/minute to 5 liters/minute), and five had critical disease (requiring mechanical ventilation with maximum 100% fraction of inspired oxygen). Nine of the patients with mild/asymptomatic COVID-19 received MAb in the outpatient setting, and only one of these patients subsequently required hospitalization for COVID-19 symptoms without any progression beyond mild COVID-19. Eighteen SOTRs (60%) were hospitalized due to COVID-19. Of these 18, three SOTRs with mild COVID-19 were hospitalized for reasons unrelated to COVID-19, and three other SOTRs with mild COVID-19 were hospitalized due to COVID-19 symptoms including fevers, diarrhea, and upper respiratory symptoms without development of hypoxemia. Two of the six hospitalized patients with mild COVID-19 received MAb—one received treatment at outpatient setting prior to admission (noted above), and the other received treatment during their hospitalization. Neither of these patients progressed to severe disease. The remaining 12 of 18 hospitalized patients had moderate, severe, or critical COVID-19. Of the six patients with severe disease, three patients had severe disease at the time of presentation, and the other three initially presented with mild disease and received MAb, but then progressed to severe disease requiring oxygen via nasal cannula. Four patients (13%) overall died; all of whom had critical disease. Of these four deaths, two (6.67%) were attributed to COVID-19, one was due to shock of unknown etiology, and one was due to aspiration pneumonia. Both deaths that were not due to COVID-19 did occur during the same hospitalization for COVID-19.

4 DISCUSSION

Our findings show a 73% reduction in the risk of COVID-19 among fully vaccinated SOTRs after receipt of two-dose mRNA vaccine or one-dose Ad26.Cov2.S. Additionally, vaccination was associated with 76% reduction in all-cause mortality. Our use of propensity score matching reduced the potential influence of major confounders, which have been associated with worse COVID-19 outcomes.

Among patients with breakthrough SARS-CoV-2 infection, severe/critical disease and death were less common in fully vaccinated SOTRs than the not fully vaccinated SOTRs (severe/critical disease: 22% vs. 37%; death due to COVID-19: 0% vs. 6.67%). Prior studies have reported a high mortality rate of SOTRs with COVID-19 in the prevaccine era, ranging from 18% to 24%.1–4 The lower death rate in our not fully vaccinated group may have been due to the inclusion of partially vaccinated patients in this group as well as improved treatments for COVID-19 including postexposure monoclonal antibodies and anti-inflammatory therapies such as tocilizumab and baricitinib.25 Importantly, all COVID-19-related deaths in our study were in unvaccinated patients. COVID-19-related hospitalization was also lower in the vaccinated group (33%) compared to the not fully vaccinated group (60%). Some hospitalizations may have been prevented with the use of monoclonal antibody in the outpatient setting, that is, three patients in the fully vaccinated and nine patients in the not fully vaccinated groups received monoclonal antibody and were not subsequently hospitalized.

While there has been significant interest in measuring the humoral immune response as a surrogate marker for vaccine efficacy, the most important outcomes are clinical endpoints including protection from SARS-CoV-2 infection and severe/critical disease, outcomes that were evaluated in COVID-19 vaccine trials in the general population but not specifically in immunocompromised patients.5–7 Lack of accounting for cellular immunity is one way in which antibody measurements alone may not fully predict the clinical protective efficacy of SARS-CoV-2 vaccination. Studies have shown decreased cellular immunity in SOTRs compared to healthy controls in response to SARS-CoV-2 vaccination.26,27 However in these same studies, cellular and humoral immune responses did not correlate with each other, with some patients having a robust cellular immune response without a humoral response. The T-cell role in vaccines in general remains poorly understood, due to a number of factors including the lack of approved commercially available assays to measure the T cell response.28 Additionally, with regard to measuring the humoral immune response to COVID-19 vaccination and infection, validated calibration of cutoffs for many of the wide array of available neutralizing antibody assays is still being investigated—making it difficult to interpret the meaning of a given antibody test.29 Our results, which show protection from infection, severe/critical disease, hospitalization, and death among fully vaccinated SOTR, suggest that measurement of antibodies should not be the sole surrogate marker for vaccine effectiveness.

Our study has several limitations. The small number of infections in our study may have been related to the relatively high vaccination...
|                          | Fully vaccinated (n = 9) | Not fully vaccinated (n = 30) | p-value |
|--------------------------|-------------------------|-------------------------------|---------|
| **Age – mean (SD)**      | 55.89 (18.22)           | 58.97 (12.20)                 | .56     |
| **Sex**                  |                         |                               | .44     |
| Male                     | 4 (44.44%)              | 19 (63.33%)                   |         |
| Female                   | 5 (55.56%)              | 11 (36.67%)                   |         |
| **Race**                 |                         |                               | .36     |
| White                    | 4 (44.44%)              | 18 (60.00%)                   |         |
| Black                    | 2 (22.22%)              | 7 (23.33%)                    |         |
| Asian                    | 1 (11.11%)              | 0 (0.00%)                     |         |
| Other                    | 2 (22.22%)              | 5 (16.67%)                    |         |
| **Ethnicity**            |                         |                               | .13     |
| Hispanic/Latino          | 5 (55.56%)              | 8 (26.67%)                    |         |
| Non-Hispanic or Latino   | 4 (44.44%)              | 22 (73.33%)                   |         |
| **Transplanted organ**   |                         |                               | .31     |
| Kidney                   | 7 (77.78%)              | 21 (70.00%)                   |         |
| Liver                    | 2 (22.22%)              | 2 (6.67%)                     |         |
| Heart                    | 0 (0%)                  | 6 (20.00%)                    |         |
| Kidney-heart             | 0 (0%)                  | 1 (3.33%)                     |         |
| **Years from transplant – Mean (SD)** | 5.08 (4.39) | 7.03 (6.52) | .41     |
| **Maintenance immunosuppression** |                      |                               |         |
| Mycophenolate            | 7 (77.78%)              | 21 (70.00%)                   | 1.00    |
| Azathioprine             | 0 (0.00%)               | 2 (6.67%)                     | 1.00    |
| Tacrolimus               | 5 (55.56%)              | 23 (76.67%)                   | .24     |
| Cyclosporine             | 1 (11.11%)              | 3 (10.00%)                    | 1.00    |
| Belatacept               | 2 (22.22%)              | 5 (16.67%)                    | .65     |
| Prednisone               | 5 (55.56%)              | 20 (66.67%)                   | .70     |
| **Rejection within 6 months** | 0                      | 0                              |         |
| **COVID-19-related treatment** |                      |                               |         |
| Monoclonal antibody      | 5 (55.56%)              | 13 (43.33%)                   | .71     |
| Remdesivir               | 2 (22.22%)              | 8 (26.67%)                    | 1.00    |
| Dexamethasone            | 2 (22.22%)              | 12 (40.00%)                   | .44     |
| Tocilizumab              | 1 (11.11%)              | 5 (16.67%)                    | 1.00    |
| **Severity of infection** |                         |                               | .59     |
| Asymptomatic/mild        | 7 (77.78%)              | 18 (60.00%)                   |         |
| Moderate                 | 0 (0.00%)               | 1 (3.33%)                     |         |
| Severe                   | 2 (22.22%)              | 6 (20.00%)                    |         |
| Critical                 | 0 (0.00%)               | 5 (16.67%)                    |         |
| **Hospitalized due to COVID-19** | 3 (33.33%) | 18 (60.00%) | .26     |
| **Death**                | 0                       | 4 (13.33%)                    | .56     |
| **Death due to COVID-19** | 0                       | 2 (6.67%)                     | 1.00    |
rate in the Connecticut population at the time of this study. Thus, our results may not be generalizable to communities with low vaccination uptake. Vaccinated patients in our study were a maximum of 6 months out from vaccination, and 39% were within 4 months of vaccination, prior to anticipated waning of immunity reported in several studies after around 6 months.30,31 Of additional importance, the SARS-CoV-2 B.1.617.2 (Delta) variant was predominant in Connecticut during our study period; hence, our findings cannot be extrapolated to infection due to B.1.1.529 (Omicron) or other variants. Our study timeframe did not evaluate for long-term risk of breakthrough infections, which may be affected by waning immunity, changes in variants, changes in public health measures (including vaccination or mask mandates and lockdowns), and ultimately COVID-19 prevalence in the community. Our center does not routinely measure antibodies postvaccination; hence, our data do not evaluate the correlation between antibody response and clinical outcomes. Our study is limited by its retrospective nature. SARS-CoV-2 infection cases may have been underestimated due to the possibility of patient’s receipt of care outside of our healthcare system and missing documentation of event. Lastly, the severity of disease among those who developed SARS-CoV-2 infection was ascertained only from the EMR documentation.

Despite concerns of decreased immune response in SOTRs due to the presence of immunosuppression, SARS-CoV-2 vaccine is effective in prevention of severe COVID-19 and death within several months after full vaccination. Vaccination, in addition to other protective strategies, such as masking and early diagnosis, may reduce poor outcomes post-COVID-19 in this vulnerable population. Due to ever-evolving SARS-CoV2 variants, future studies should continuously evaluate the efficacy of current vaccine strategies.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

AUTHOR CONTRIBUTIONS

M T contributed to concept/design, drafting of the article data collection, data interpretation, and critical revision of the article. M M A contributed to concept/design and critical revision of the article. E C contributed to data collection and critical revision of the article. G G contributed to statistical analysis, data interpretation, and critical revision of the article. Y G contributed to statistical analysis, data interpretation, and critical revision of the article. C F P contributed to statistical analysis and critical revision of the article. M M contributed to concept/design, data collection, data interpretation, and critical revision of the article.

ORCID

Mollie Tucker https://orcid.org/0000-0003-2326-1222
Marwan M. Azar https://orcid.org/0000-0001-5498-5042
Elizabeth Cohen https://orcid.org/0000-0001-7853-4107
Geliang Gan https://orcid.org/0000-0001-6984-754X
Yanhong Deng https://orcid.org/0000-0002-4333-468X
Carlo Foppiano Palacios https://orcid.org/0000-0002-2698-981X

Maricar Malinis https://orcid.org/0000-0002-5720-9994

REFERENCES

1. Kates OS, Haydel BM, Florman SS, et al. COVID-19 in solid organ transplant: a multi-center cohort study. Clin Infect Dis. 2020;73:e4090–e4099. https://doi.org/10.1093/cid/ciaa1097
2. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: initial report from the US epicenter. Am J Transplant. 2020;20(7):1800–1808. https://doi.org/10.1111/aaj.15941
3. Elias M, Pievani D, Randoux C, et al. COVID-19 infection in kidney transplant recipients: disease incidence and clinical outcomes. J Am Soc Nephrol. 2020;31(10):2413–2423. https://doi.org/10.1681/ASN.2020050639
4. Fisher AM, Schlauch D, Mulloy M, et al. Outcomes of COVID-19 in hospitalized solid organ transplant recipients compared to a matched cohort of non-transplant patients at a national healthcare system in the United States. Clin Transplant. 2021;35(4):e14216. https://doi.org/10.1111/ctr.14216
5. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. https://doi.org/10.1056/NEJMoa2034577
6. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. https://doi.org/10.1056/NEJMoa2035389
7. Sadoff J, Gray G, Vandeboch A, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–2201. https://doi.org/10.1056/NEJMoa2101544
8. Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect. 2021;27:1652–1657. https://doi.org/10.1016/j.cmi.2021.06.036
9. Rabinovich L, Grupper A, Baruch R, et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol. 2021;75(2):435–438. https://doi.org/10.1016/j.jhep.2021.04.020
10. Grupper A, Rabinovich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021;21(8):2719–2726. https://doi.org/10.1111/ajt.16415
11. Itzhaki Ben Zadok O, Shaul AA, Ben-Avraham B, et al. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study. Eur J Heart Fail. 2021;23:1555–1559. https://doi.org/10.1002/ejhf.2199
12. Havlin J, Svorcova M, Dvorackova E, et al. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients. J Heart Lung Transplant. 2021;40(8):754–758. https://doi.org/10.1016/j.hejlun.2021.05.004
13. Del Bello A, Abravanel F, Marion O, et al. Efficiency of a boost with BNT162b2 mRNA COVID-19 vaccine in kidney transplant recipients: a multi-center cohort study. Am J Transplant. 2021;22:322–323. https://doi.org/10.1111/ajt.16775
14. Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385.10:1357–1367. https://doi.org/10.1056/NEJMoa2105063
15. U.S. Food & Drug Administration. FDA news release: Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals. August 12, 2021. Accessed December 20, 2021. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised
16. Qin CX, Moore LW, Anjan S, et al. Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients. Transplantation. 2021;105:e265–e266. https://doi.org/10.1097/TP.0000000000003907
17. Aslam S, Liu J, Sigler R, et al. COVID-19 vaccination is protective of clinical disease in solid organ transplant recipients. Transpl Infect Dis. 2022;24:e13788. https://doi.org/10.1111/tid.13788

18. NIH Covid-19 treatment guidelines: clinical spectrum of SARS-CoV-2 infection. National Institutes of Health. October 19, 2021. Accessed January 2, 2022. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/

19. Yasmin F, Najeeb H, Moeed A, et al. COVID-19 vaccine hesitancy in the United States: a systematic review. Front Public Health. 2021;9:770985. https://doi.org/10.3389/fpubh.2021.770985

20. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature, 2020;584(7821):430–436. https://doi.org/10.1038/s41586-020-2521-4

21. Centers for Disease Control and Prevention. Science brief: evidence used to update the list of underlying medical conditions associated with higher risk for severe COVID-19. February 15, 2022. Accessed April 8, 2022. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/underlying-evidence-table.html#anchor_1647452432421

22. Colmenero J, Rodríguez-Peralvarez M, Salcedo M, et al. Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients. J Hepatol. 2021;74(1):148–155. https://doi.org/10.1016/j.jhep.2020.07.040

23. Barros AJ, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:21. https://doi.org/10.1186/1471-2288-3-21

24. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702–706. https://doi.org/10.1093/aje/kwh090

25. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020;ciaa478. https://doi.org/10.1093/cid/ciaa478

26. Yanis A, Haddad Z, Spiker AJ, et al. Humoral and cellular immune responses to the SARS-CoV-2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls. Transpl Infect Dis. 2021;24:e13772. https://doi.org/10.1111/tid.13772

27. Cucchiari D, Egri N, Bodro M, et al. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients. Am J Transplant. 2021;21(8):2727–2739. https://doi.org/10.10111/ajt.16701

28. Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83–100. https://doi.org/10.1038/s41577-020-00479-7

29. Zhu F, Althaus T, Tan CW, et al. WHO international standard for SARS-CoV-2 antibodies to determine markers of protection. Lancet Microbe. 2022;3(2):e81–e82. https://doi.org/10.1016/S2666-5247(21)00307-4

30. Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385(24):e85. https://doi.org/10.1056/NEJMoa2114228

31. Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021;385(24):e83. https://doi.org/10.1056/NEJMoa2114114

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Tucker M, Azar MM, Cohen E, et al. Evaluating clinical effectiveness of SARS-CoV-2 vaccine in solid organ transplant recipients: A propensity score matched analysis. Transpl Infect Dis. 2022;24:e13876. https://doi.org/10.1111/tid.13876